Loading...
XSHE
301206
, Last price  
Name

Shandong Sanyuan Biotechnology Co Ltd

Chart & performance

D1W1MN
XSHE:301206 chart
P/E
—
P/S
—
EPS
0.45
Vol. 1Y
—
Shs. 5Y
5.55%
Rev. 5Y
-17.26%
Div Yld LY
—
Div Yld TTM
—
Revenues
650m
-8.89%
19,204,99120,060,62320,060,62340,078,15488,904,484120,955,110292,203,950476,759,627783,182,2291,675,320,0341,675,320,034674,905,595674,905,595499,500,774712,904,206649,511,864
Net income
91m
-12.90%
354,815516,057516,0582,036,88413,941,72318,704,47668,088,457136,306,838232,572,772535,415,008535,415,012163,686,641163,686,64555,981,921104,951,34091,410,640
CFO
23m
P
3,889,3183,195,7489,498,96322,955,27020,247,23865,461,977149,214,237217,367,948642,075,35684,264,65457,310,770-13,649,51022,815,737
Dividend
Jul 15, 20260.5 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Sanyuan Biotechnology Co., Ltd., established in 2007 and headquartered in Binzhou, China, specializes in the development, manufacturing, and sale of erythritol and various compound sugar products within the Chinese market. These versatile products find widespread application across numerous industries, serving as ingredients in items such as table and flavored sugars, beverages, candies, chocolate products, baked goods, health foods, pharmaceuticals, cosmetics, and diverse chemical formulations. The company also extends its reach beyond China, distributing its products internationally to regions including Europe, the United States, East Asia, Southeast Asia, Australia, New Zealand, and Africa.
IPO date
Feb 10, 2022
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT